USE OF TAXOL (PACLITAXEL) IN BREAST-CANCER

被引:21
作者
HORTOBAGYI, GN
HOLMES, FA
THERIAULT, RL
BUZDAR, AU
机构
[1] Department of Breast and Gynecologic Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX
关键词
BREAST CANCER; CHEMOTHERAPY; TAXOL; PACLITAXEL; DOXORUBICIN;
D O I
10.1159/000227413
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Taxol (paclitaxel) has demonstrated good antitumor activity against metastatic breast cancer (MBC) in phase II trials. The drug is usually well tolerated. However, severe myelosuppression, including rapidly reversible neutropenia, may necessitate dose reductions and may ultimately limit its use as a longterm treatment. Sequential or simultaneous administration of Taxol and doxorubicin may enhance response rates. There appears to be no complete cross-resistance between the two drugs. Current trials are exploring the best way to deliver this combination while keeping dose-limiting toxicity to a minimum. Additionally, single-agent trials are evaluating Taxol in extensively pretreated MBC. The results of these trials are awaited with interest.
引用
收藏
页码:29 / 32
页数:4
相关论文
共 13 条
[1]  
FALKSON G, 1983, CANCER TREAT REP, V67, P189
[2]  
Fisherman J., 1992, P AM SOC CLIN ONCOL, V11, P57
[3]  
HAYWARD JL, 1977, CANCER, V39, P1289, DOI 10.1002/1097-0142(197703)39:3<1289::AID-CNCR2820390340>3.0.CO
[4]  
2-F
[5]   PHASE-II TRIAL OF TAXOL, AN ACTIVE-DRUG IN THE TREATMENT OF METASTATIC BREAST-CANCER [J].
HOLMES, FA ;
WALTERS, RS ;
THERIAULT, RL ;
FORMAN, AD ;
NEWTON, LK ;
RABER, MN ;
BUZDAR, AU ;
FRYE, DK ;
HORTOBAGYI, GN .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (24) :1797-1805
[6]  
HOLMES FA, IN PRESS 4TH P INT C
[7]  
HOLMES FA, 1992, P AN M AM SOC CLIN, V11, P60
[8]   OVERVIEW OF NEW TREATMENTS FOR BREAST-CANCER [J].
HORTOBAGYI, GN .
BREAST CANCER RESEARCH AND TREATMENT, 1992, 21 (01) :3-13
[9]  
LOBER J, 1983, CANCER, V52, P1570, DOI 10.1002/1097-0142(19831101)52:9<1570::AID-CNCR2820520905>3.0.CO
[10]  
2-W